Exparel
Manufacturing · Florida, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
5401 W Kennedy Blvd Ste 890, Tampa, Flor...Phone Number
(973) 254-3560Website
www.exparel.comRevenue
$6.5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Exparel
Exparel is a pharmaceutical company specializing in innovative pain management solutions for the hospital sector. The company produces a bupivacaine liposome injectable suspension indicated for postsurgical local analgesia in patients 6 years and older, and for regional analgesia in adults. Exparel's flagship product utilizes multivesicular liposome technology to deliver medication over an extended period, representing an advancement in local anesthetic applications for surgical settings. The company's formulation is designed to reduce pain scores and decrease the need for additional pain medications following surgical procedures. With multiple locations, Exparel serves the healthcare industry by providing specialized pharmaceutical products focused on improving patient recovery experiences.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Exparel your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Exparel is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Exparel
Website visits: Recent activity has been detected on your website
Click to see if Exparel had a recent Job posting/layoffs
Earning: See what the market has to say on Exparel recently announced quarterly report
Check if Exparel has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Exparel has new funding data
Product Launch: Get notified when Exparel launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Exparel, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Exparel as Masked Content
Find more new buyers
Compare Similar Companies to Exparel
Compare insights from companies similar to Exparel, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Exparel
$6.5M
11-50
Private
-
-
N/A
Company Profile Activity
Activity Insights
Exparel is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Exparel is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Exparel.
Exparel Tech Stack
A closer look at the technologies used by Exparel
Exparel News & Media
Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®
-- Expands Patient Access to Non-Opioid Postsurgical Pain Management Across Outpatient Settings -- BRISBANE, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that UnitedHealthcare now provides separate reimbursement for EXPAREL® (bupivacaine liposome injectable suspension) across outpatient settings, including hospital outpatPacira BioSciences Reports Real-World Study Showing EXPAREL® Use Was Associated with Reduced Opioid Use and Healthcare Costs in Patients Undergoing Total Shoulder Arthroplasty
Findings presented at ISPOR 2026 showed lower opioid consumption, reduced healthcare costs, and fewer opioid-related adverse events associated with EXPAREL usePacira BioSciences Reports First Quarter 2026 Financial Results
-- Total revenue of $177 million, reflecting increase of 5 percent over first quarter 2025 driven by growth across commercial portfolio, including EXPAREL volume growth of 7 percent -- -- Completed enrollment in Phase 3 registrational study of ZILRETTA in osteoarthritis pain of the shoulder; study on track for topline readout by end of year --Real-World Data on EXPAREL® Shows Reduced Opioid Use and Lower Total Medical Costs in Medicare Patients Undergoing Total Hip Arthroplasty
-- Findings show significant reductions in opioid consumption, healthcare resource utilization, and total medical costs -- -- Findings show significant reductions in opioid consumption, healthcare resource utilization, and total medical costs --
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Exparel
Sign Up For FreeTo access detailed company insights
Exparel is a pharmaceutical company specializing in innovative pain management solutions for the hospital sector. The company produces a bupivacaine liposome injectable suspension indicated for postsurgical local analgesia in patients 6 years and older, and for regional analgesia in adults. Exparel's flagship product utilizes multivesicular liposom... Read More
